Biopharmaceutical Contract Manufacturing Market in North America Size, Share & Trends by 2031

0
2

The Biopharmaceutical Contract Manufacturing market in North America is expected to maintain strong growth momentum due to the rising prevalence of chronic diseases and growing demand for biologic therapies. Contract manufacturers are playing a critical role in supporting efficient and scalable production capabilities.

According to The Insight Partners,The biopharmaceutical contract manufacturing market size is projected to reach US$ 101.05 billion by 2031 from US$ 40.99 billion in 2024. The market is expected to register a CAGR of 13.8% during 2025–2031. Advanced manufacturing technologies are emerging as a significant trend in the biopharmaceutical contract manufacturing market.

 

Market Overview

The Biopharmaceutical contract manufacturing involves outsourcing the production of biologic drugs and therapies to third-party manufacturing service providers. These companies offer expertise in process development, scale-up, production, quality assurance, packaging, and regulatory compliance. The growing complexity of biologic medicines has made contract manufacturing an essential component of the pharmaceutical value chain.Biologics, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies, require sophisticated manufacturing infrastructure and regulatory expertise. 

Get Sample PDF@ https://www.theinsightpartners.com/sample/TIPRE00005512 

Key Market Drivers

  • Rising Demand for Biologics:-One of the primary growth drivers for the biopharmaceutical contract manufacturing market is the rising demand for biologic therapies. Biologics have become a cornerstone of modern medicine, particularly in the treatment of cancer, autoimmune diseases, metabolic disorders, and infectious diseases.The increasing prevalence of chronic illnesses worldwide has accelerated the development and adoption of innovative biologic therapies. 
  • Growing Need for Cost Efficiency and Flexibility:-Contract manufacturing provides pharmaceutical companies with greater operational flexibility while reducing production costs. Establishing in-house biologics production facilities requires substantial capital expenditure and regulatory approvals. By outsourcing manufacturing activities, companies can focus on clinical development, research, and marketing while maintaining access to high-quality production capabilities.Furthermore, CMOs offer scalable manufacturing solutions that help biopharmaceutical companies respond quickly to fluctuating market demand. This flexibility is particularly important in the rapidly evolving healthcare sector, where product demand can change significantly within short periods.
  • Emerging Opportunity: Personalized Medicine
  • The rapid growth of personalized medicine presents significant opportunities for biopharmaceutical contract manufacturers. Personalized therapies are designed according to individual patient genetic profiles, lifestyles, and disease characteristics, resulting in more targeted and effective treatments.Innovations in genomics, biotechnology, and diagnostics have accelerated the development of personalized medicines, including cell therapies, gene therapies, and precision oncology treatments. 

Market Segmentation Analysis

By Product Type

Based on product type, the market is segmented into biologics and biosimilars. The biologics segment accounted for the largest share of the market in 2024, reflecting the growing adoption of innovative biological therapies across multiple therapeutic areas. 

By Source

The market is categorized into microbial and mammalian sources. The microbial segment dominated the market in 2024 and is anticipated to continue expanding due to its cost-effectiveness and efficiency in producing various biopharmaceutical products. The microbial segment is also expected to witness significant growth during the forecast period. 

By Application

On the basis of application, the market is divided into commercial and clinical segments. The commercial segment accounted for the largest market share in 2024 as more biologic products moved from clinical development into commercial production.

By Therapeutic Area

The therapeutic area segment includes oncology, autoimmune disorders, respiratory disorders, metabolic disorders, neurology, infectious diseases, and others. Oncology represented the leading therapeutic segment and is anticipated to record strong growth due to the increasing prevalence of cancer and growing demand for innovative biologic cancer therapies. 

Regional Analysis

North America

North America held the largest share of the global biopharmaceutical contract manufacturing market in 2024, accounting for approximately 40.2% of total revenue. The region benefits from a mature pharmaceutical industry, advanced healthcare infrastructure, substantial research investments, and a supportive regulatory environment. 

Asia Pacific

Asia Pacific is expected to emerge as the fastest-growing regional market, registering a CAGR of approximately 14.3% during the forecast period. Factors such as increasing healthcare expenditure, growing pharmaceutical manufacturing capabilities, expanding biotechnology sectors, and supportive government initiatives are driving market growth across countries including China, India, Japan, and South Korea. 

Europe

Europe continues to serve as an important hub for biopharmaceutical manufacturing. Countries such as Germany, France, Switzerland, and the United Kingdom have well-established pharmaceutical industries and advanced manufacturing capabilities. European contract manufacturers are expanding into high-growth areas such as biologics, cell therapies, gene therapies, and high-potency active pharmaceutical ingredients. 

Competitive Landscape

The biopharmaceutical contract manufacturing market is highly competitive, with leading companies continually investing in capacity expansion, technological advancements, and strategic partnerships.Major market participants include:

  • Boehringer Ingelheim International GmbH

  • Thermo Fisher Scientific Inc.

  • Lonza Group AG

  • Merck KGaA

  • AbbVie Inc.

  • Samsung Biologics Co. Ltd.

  • WuXi Biologics Inc.

  • Ajinomoto Co., Inc.

  • AGC Biologics

  • Cytiva 

Future Outlook

The future of the biopharmaceutical contract manufacturing market appears highly promising. Rising demand for biologics, increasing outsourcing strategies, technological innovation, and the growing importance of personalized medicine are expected to create substantial growth opportunities over the coming years.As pharmaceutical companies seek faster, more efficient, and cost-effective production solutions, contract manufacturers will continue to play a pivotal role in global healthcare innovation.

About The Insight Partners

The Insight Partners delivers market intelligence and consulting services to help clients make informed decisions. The firm covers industries such as Aerospace and Defense, Automotive and Transportation, Semiconductor and Electronics, Biotechnology, Healthcare IT, Manufacturing, Medical Devices, Technology, Media, and Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Ankit Mathur

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Also Available in :

Buscar
Categorías
Read More
Health
Laser Therapy for Keloid Scars: Smooth and Flatten Skin
Keloid scars are more than just a cosmetic concern—they can affect confidence, comfort, and...
By mominsaudi321 2026-04-25 09:37:36 0 996
Art
Nutraceutical Demand Opens New Growth Opportunities for Concentrated Milk Fat
Food and beverage manufacturers are emphasizing ingredients that provide taste, consistent...
By PolarisNews 2026-09-23 04:25:46 0 254
Other
Whipping Cream Market Size, Share, Trends & Forecast 2033
In-Depth Study on Executive Summary Whipping Cream Market Size and ShareCAGR Value The global...
By mahir007 2026-11-19 11:17:10 0 2
Other
Diabetic Sores: Recognizing Wounds and Protecting Skin Health
Diabetic sores can be more difficult to heal than ordinary cuts or minor injuries. Diabetes may...
By reforesthosting 2026-09-25 12:15:24 0 267
Other
Automotive Composite Materials Market Outlook 2033: US$ 26.07 Billion Valuation at 8.57% CAGR
The Automotive Composite Materials Market size is expected to reach US$ 26.07 Billion by 2033...
By businesstrends 2026-09-29 06:58:30 0 2K
AC Mingle https://acmingle.com